Quanterix Corp

More Details of Quanterix Corp Company

Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. It also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. It has completed over 2,200 projects for 480 customers using its Simoa platforms.

Company Info

Ticker SymbolQTRX

Company nameQuanterix Corp

IPO dateDec 07, 2017

CEODr. Masoud Toloue, Ph.D.

Number of employees471

Security typeOrdinary Share

Fiscal year-endDec 07

Address900 Middlesex Turnpike

CityBILLERICA

Stock exchangeNASDAQ Global Market Consolidated

CountryUnited States of America

Postal code01821

Phone16173019400

Websitehttps://www.quanterix.com/

Ticker SymbolQTRX

IPO dateDec 07, 2017

CEODr. Masoud Toloue, Ph.D.

Company Executives

Name

Name/Position

Position

Shareholding

Change

Dr. David R. Walt, Ph.D.

Independent Director

1.86M

+0.12%

Dr. Masoud Toloue, Ph.D.

President, Chief Executive Officer, Director

288.86K

-0.43%

Mr. William P. (Bill) Donnelly

Independent Chairman of the Board

133.06K

+5.49%

Ms. Karen A. Flynn

Independent Director

26.41K

--

Ms. Vandana Sriram, CPA

Chief Financial Officer, Treasurer

15.30K

+34.46%

Mr. Scott Mendel

Director

4.19K

--

Mr. Jeffrey Thomas (Jeff) Elliott

Independent Director

3.96K

-79.63%

Dr. Myla P. Lai-Goldman, M.D.

Director

2.94K

--

Dr. Ivana Magov Evi-liebisch, J.D., Ph.D.

Independent Director

--

Mr. Paul M. Meister

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Dr. David R. Walt, Ph.D.

Independent Director

1.86M

+0.12%

Dr. Masoud Toloue, Ph.D.

President, Chief Executive Officer, Director

288.86K

-0.43%

Mr. William P. (Bill) Donnelly

Independent Chairman of the Board

133.06K

+5.49%

Ms. Karen A. Flynn

Independent Director

26.41K

--

Ms. Vandana Sriram, CPA

Chief Financial Officer, Treasurer

15.30K

+34.46%

Mr. Scott Mendel

Director

4.19K

--

Revenue Breakdown

Currency: USDUpdated: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q2

FY2024Q1

FY2023

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

By BusinessUSD

Name

Revenue

Proportion

Product revenue

20.74M

68.51%

Service and other revenue

8.76M

28.95%

Collaboration and license revenue

771.00K

2.55%

By RegionUSD

Name

Revenue

Proportion

North America

19.38M

64.01%

EMEA

6.63M

21.92%

Asia Pacific

4.26M

14.07%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Product revenue

20.74M

68.51%

Service and other revenue

8.76M

28.95%

Collaboration and license revenue

771.00K

2.55%

Shareholding Stats

Updated: Sat, Aug 16

Shareholders

Shareholder Types

Shareholders

Proportion

Portolan Capital Management, L.L.C.

7.82%

Columbia Threadneedle Investments (UK)

6.73%

BlackRock Institutional Trust Company, N.A.

5.70%

The Vanguard Group, Inc.

5.44%

Kent Lake PR LLC

4.50%

Other

69.81%

Shareholders

Proportion

Portolan Capital Management, L.L.C.

7.82%

Columbia Threadneedle Investments (UK)

6.73%

BlackRock Institutional Trust Company, N.A.

5.70%

The Vanguard Group, Inc.

5.44%

Kent Lake PR LLC

4.50%

Other

69.81%

Shareholder Types

Shareholders

Proportion

Investment Advisor/Hedge Fund

34.26%

Investment Advisor

20.99%

Hedge Fund

13.18%

Individual Investor

6.47%

Research Firm

3.94%

Pension Fund

0.67%

Bank and Trust

0.27%

Family Office

0.13%

Venture Capital

0.12%

Other

19.97%

Institutional Shareholding

Updated: Tue, Jul 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q2

391

36.46M

81.18%

-12.95M

2025Q1

401

40.45M

104.19%

-6.42M

2024Q4

388

38.02M

98.63%

-6.28M

2024Q3

386

36.47M

95.03%

-5.94M

2024Q2

394

35.66M

93.20%

-9.57M

2024Q1

395

35.56M

93.43%

-9.17M

2023Q4

388

34.77M

91.99%

-10.35M

2023Q3

382

36.53M

97.35%

-9.84M

2023Q2

388

36.74M

98.24%

-9.95M

2023Q1

389

37.25M

100.03%

-8.36M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

Portolan Capital Management, L.L.C.

2.96M

7.63%

+375.57K

+14.51%

Mar 31, 2025

Columbia Threadneedle Investments (UK)

3.00M

7.72%

+237.57K

+8.60%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

2.68M

6.91%

-89.03K

-3.21%

Mar 31, 2025

The Vanguard Group, Inc.

2.53M

6.5%

+316.41K

+14.32%

Mar 31, 2025

Kent Lake PR LLC

2.92M

7.53%

+279.82K

+10.58%

Mar 31, 2025

Walt (David R)

1.86M

4.79%

+370.00K

+24.84%

Jun 13, 2025

Invenomic Capital Management LP

902.04K

2.32%

+546.67K

+153.83%

Mar 31, 2025

William Blair Investment Management, LLC

1.11M

2.85%

+43.96K

+4.14%

Mar 31, 2025

Columbia Threadneedle Investments (US)

716.23K

1.84%

+271.74K

+61.14%

Mar 31, 2025

Easterly Investment Partners LLC

1.33M

3.41%

+370.63K

+38.81%

Mar 31, 2025

Related ETFs

Name

Proportion

No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

5.430USD

Quanterix Corp

5.430

Overview

Company

Financials

Analysis